Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Gynecologic 1Breast 1

Conditions

Breast Neoplasms 513Breast Neoplasms, Male 79Ovarian Neoplasms 54Triple Negative Breast Neoplasms 46Lung Neoplasms 43Colonic Neoplasms 41Prostatic Neoplasms 38Neoplasms 38Neoplasm Metastasis 35Carcinoma, Non-Small-Cell Lung 33Melanoma 31Pancreatic Neoplasms 29Colorectal Neoplasms 28Stomach Neoplasms 24Carcinoma, Ovarian Epithelial 24Endometrial Neoplasms 23Carcinoma, Renal Cell 23Inflammatory Breast Neoplasms 21Brain Neoplasms 20Carcinoma, Intraductal, Noninfiltrating 19Breast Carcinoma In Situ 19Rectal Neoplasms 18Urinary Bladder Neoplasms 17Lymphoma, Non-Hodgkin 17Lymphoma, T-Cell, Cutaneous 16Leukemia, Lymphocytic, Chronic, B-Cell 16Esophageal Neoplasms 16Uterine Cervical Neoplasms 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Lymphoma 15

Interventions

talazoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Advanced Ovarian Cancer × Breast × Clear all
NCT01989546 2021-02-23

Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
9 enrolled 11 charts
BreastGynecologicOther solid neoplasm

Advanced Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡